Olmesartán/Amlodipino/Hidroclorotiazida Cinfa (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartán/Amlodipino/Hidroclorotiazida Cinfa, is a angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension, often in combination with other antihypertensive agents, and is suitable for adult patients. GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/amlodipine/hydrochlorothiazide is used to manage blood pressure through several complementary mechanisms.

- Hypertension: helps achieve target blood pressure levels in adults. - High‑risk cardiovascular patients: reduces the risk of stroke and heart attack when combined with lifestyle changes. - Edema associated with hypertension: aids fluid reduction when added to a diuretic regimen.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness: especially after the first doses. - Flushing: transient warmth sensation. - Fatigue: general tiredness. - Cough: dry, non‑productive.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, tongue, or throat. - Severe hypotension: symptomatic low blood pressure. - Electrolyte disturbances: significant changes in potassium or sodium levels. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: elevated liver enzymes. - Blood dyscrasias: rare blood cell abnormalities.

When prescribing this combination, clinicians should consider patient‑specific factors and monitor relevant parameters.

- Renal function: assess baseline creatinine and eGFR before initiation. - Electrolytes: monitor serum potassium and sodium regularly. - Hepatic status: evaluate liver function tests in patients with known disease. - Pregnancy: avoid use during pregnancy due to fetal risk. - Elderly patients: start at lower doses and titrate cautiously. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan/amlodipine/hydrochlorothiazide may interact with several medicines; careful review is recommended.

Major Interactions (Avoid): - Potassium‑rich supplements: risk of hyper‑kalemia. - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase amlodipine concentrations. - Antidiabetic drugs: potential enhancement of hypoglycaemic effect. - Other antihypertensives: additive blood‑pressure lowering leading to hypotension.